{"id":49045,"date":"2022-09-30T19:02:23","date_gmt":"2022-09-30T17:02:23","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/athersys-to-host-business-update-conference-call-on-october-6th\/"},"modified":"2022-09-30T19:02:23","modified_gmt":"2022-09-30T17:02:23","slug":"athersys-to-host-business-update-conference-call-on-october-6th","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/athersys-to-host-business-update-conference-call-on-october-6th\/","title":{"rendered":"Athersys to Host Business Update Conference Call on October 6th"},"content":{"rendered":"
\n

CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX)<\/b>, a regenerative medicine company developing MultiStem\u00ae<\/sup> (invimestrocel) for critical care indications, announced today it will host a business update conference call on October 6, 2022 at 4:00 pm Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert \u201cWillie\u201d Mays, Executive Vice President Regenerative Medicine and Head of Neuroscience, will provide an overview of the company\u2019s accomplishments since its recently announced restructuring.\n<\/p>\n

<\/a><\/p>\n\n\n\n\n\n
\n

\nDate\n<\/p>\n<\/td>\n

\n

\nOctober 6, 2022\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTime\n<\/p>\n<\/td>\n

\n

\n4:00 p.m. (Eastern Time)\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nLive webcast registration\n<\/p>\n<\/td>\n

\n

\nWebcast link<\/a>\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nPhone registration\n<\/p>\n<\/td>\n

\n

\nCall registration link<\/a>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nIn lieu of a live question and answer session, management encourages participants to submit questions in advance to ir@athersys.com<\/a>. A replay of the event will be available in the Investors section of www.athersys.com<\/a>.\n<\/p>\n

\nAbout MultiStem\u00ae<\/sup><\/b>\n<\/p>\n

\nMultiStem\u00ae<\/sup> (invimestrocel) cell therapy is a patented regenerative medicine product in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. MultiStem therapy\u2019s potential for multidimensional therapeutic impact distinguishes it from traditional biopharmaceutical therapies focused on a single mechanism of benefit. The therapy represents a unique \u201coff-the-shelf\u201d stem cell product that can be manufactured in a scalable manner, may be stored for years in frozen form, and is administered without tissue matching or the need for immune suppression. Based upon its efficacy profile, its novel mechanisms of action, and a favorable and consistent tolerability demonstrated in clinical studies, we believe that MultiStem therapy could provide a meaningful benefit to patients, including those suffering from serious diseases and conditions with unmet medical need.\n<\/p>\n

\nAbout Athersys<\/b>\n<\/p>\n

\nAthersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem\u00ae cell therapy product, a patented, adult-derived \u201coff-the-shelf\u201d stem cell product, initially for disease indications in the neurological, inflammatory and immune, and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance MultiStem cell therapy toward commercialization. Investors and others should note that we may post information about the Company on our website at www.athersys.com<\/a> and\/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms. It is possible that the postings could include information deemed to be material information. Therefore, we encourage investors, the media and others interested in the Company to review the information we post on our website at www.athersys.com<\/a> and on our social media accounts. Follow Athersys on Twitter at www.twitter.com\/athersys<\/a>. Information that we may post about the Company on our website and\/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. You should not place undue reliance on forward-looking statements contained on our website and\/or on our accounts on Twitter, Facebook, LinkedIn or other social media platforms, and we undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nAthersys<\/b>
Ellen Gurley
\n
Manager of Corporate Communications and Investor Relations
\n
ir@athersys.com<\/a>\n<\/p>\n

\nLHA Investor Relations<\/b>
Tirth T. Patel
\n
212-201-6614
\n
tpatel@lhai.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem\u00ae (invimestrocel) for critical care indications, announced today it will host a business update conference call on October 6, 2022 at 4:00 pm Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert \u201cWillie\u201d Mays, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-49045","6":"format-standard","7":"category-industry"},"yoast_head":"\nAthersys to Host Business Update Conference Call on October 6th - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/athersys-to-host-business-update-conference-call-on-october-6th\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Athersys to Host Business Update Conference Call on October 6th - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem\u00ae (invimestrocel) for critical care indications, announced today it will host a business update conference call on October 6, 2022 at 4:00 pm Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert \u201cWillie\u201d Mays, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/athersys-to-host-business-update-conference-call-on-october-6th\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-30T17:02:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20220929005765\/en\/770681\/21\/Athersys_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-host-business-update-conference-call-on-october-6th\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-host-business-update-conference-call-on-october-6th\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Athersys to Host Business Update Conference Call on October 6th\",\"datePublished\":\"2022-09-30T17:02:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-host-business-update-conference-call-on-october-6th\\\/\"},\"wordCount\":586,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-host-business-update-conference-call-on-october-6th\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220929005765\\\/en\\\/770681\\\/21\\\/Athersys_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-host-business-update-conference-call-on-october-6th\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-host-business-update-conference-call-on-october-6th\\\/\",\"name\":\"Athersys to Host Business Update Conference Call on October 6th - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-host-business-update-conference-call-on-october-6th\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-host-business-update-conference-call-on-october-6th\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220929005765\\\/en\\\/770681\\\/21\\\/Athersys_logo.jpg\",\"datePublished\":\"2022-09-30T17:02:23+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-host-business-update-conference-call-on-october-6th\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-host-business-update-conference-call-on-october-6th\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-host-business-update-conference-call-on-october-6th\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220929005765\\\/en\\\/770681\\\/21\\\/Athersys_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20220929005765\\\/en\\\/770681\\\/21\\\/Athersys_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/athersys-to-host-business-update-conference-call-on-october-6th\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Athersys to Host Business Update Conference Call on October 6th\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Athersys to Host Business Update Conference Call on October 6th - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/athersys-to-host-business-update-conference-call-on-october-6th\/","og_locale":"en_US","og_type":"article","og_title":"Athersys to Host Business Update Conference Call on October 6th - Pharma Trend","og_description":"CLEVELAND–(BUSINESS WIRE)–Athersys, Inc. (NASDAQ: ATHX), a regenerative medicine company developing MultiStem\u00ae (invimestrocel) for critical care indications, announced today it will host a business update conference call on October 6, 2022 at 4:00 pm Eastern Time. Dan Camardo, Chief Executive Officer, Maia Hansen, Chief Operating Officer, Kasey Rosado, Interim Chief Financial Officer, and Robert \u201cWillie\u201d Mays, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/athersys-to-host-business-update-conference-call-on-october-6th\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-30T17:02:23+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20220929005765\/en\/770681\/21\/Athersys_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/athersys-to-host-business-update-conference-call-on-october-6th\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/athersys-to-host-business-update-conference-call-on-october-6th\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Athersys to Host Business Update Conference Call on October 6th","datePublished":"2022-09-30T17:02:23+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/athersys-to-host-business-update-conference-call-on-october-6th\/"},"wordCount":586,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/athersys-to-host-business-update-conference-call-on-october-6th\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220929005765\/en\/770681\/21\/Athersys_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/athersys-to-host-business-update-conference-call-on-october-6th\/","url":"https:\/\/pharma-trend.com\/en\/athersys-to-host-business-update-conference-call-on-october-6th\/","name":"Athersys to Host Business Update Conference Call on October 6th - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/athersys-to-host-business-update-conference-call-on-october-6th\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/athersys-to-host-business-update-conference-call-on-october-6th\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20220929005765\/en\/770681\/21\/Athersys_logo.jpg","datePublished":"2022-09-30T17:02:23+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/athersys-to-host-business-update-conference-call-on-october-6th\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/athersys-to-host-business-update-conference-call-on-october-6th\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/athersys-to-host-business-update-conference-call-on-october-6th\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20220929005765\/en\/770681\/21\/Athersys_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20220929005765\/en\/770681\/21\/Athersys_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/athersys-to-host-business-update-conference-call-on-october-6th\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Athersys to Host Business Update Conference Call on October 6th"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49045","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49045"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49045\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49045"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49045"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}